Prostamax
Evidence: DExperimental / Early Research
Evidence Snapshot
Regulatory Context
Prostamax is not to be represented as an approved prostate therapy.
Research Takeaway
Prostamax is a short synthetic KEDP peptide (Lys-Glu-Asp-Pro) in the Khavinson bioregulator lineage. Patent RU2177802C1 explicitly claims the tetrapeptide, names Prostamax as the associated trade name, and confirms it is prepared by classical peptide synthesis in solution -- distinct from Prostatilen, an animal prostate-tissue-derived polypeptide preparation.
See all 6 evidence claims →Quick Summary
Prostamax is a short synthetic peptide in the Khavinson bioregulator lineage, confirmed by patent RU2177802C1 as the tetrapeptide Lys-Glu-Asp-Pro (KEDP). It has been studied for chromatin effects and in experimental prostatitis/BPH animal models; it must not be confused with Prostatilen or other prostate tissue extracts.
Mechanism & Research Overview
Direct indexed work reports effects on chromatin organization in human lymphocyte preparations.
Evidence Claims
Individual scientific statements drawn from the sources cited below, each shown with the specific evidence boundary that statement does not establish.
Supported
Prostamax is a short synthetic KEDP peptide (Lys-Glu-Asp-Pro) in the Khavinson bioregulator lineage. Patent RU2177802C1 explicitly claims the tetrapeptide, names Prostamax as the associated trade name, and confirms it is prepared by classical peptide synthesis in solution -- distinct from Prostatilen, an animal prostate-tissue-derived polypeptide preparation.
Sources: RU2177802C1 -- Tetrapeptide regulating prostate function, pharmacological agent based on thereof and method of its using; Chromatin changes in old age involving Prostamax (Lys-Glu-Asp-Pro)
Supported
Direct indexed work reports effects on chromatin organization in human lymphocyte preparations.
Sources: Prostamax effects on heterochromatin / human lymphocytes; Chromatin changes in old age involving Prostamax (Lys-Glu-Asp-Pro)
Supported
Animal models report reduced inflammation signs and prevention of sclerotic/atrophic changes in experimental chronic aseptic prostatitis, and additional exact-sequence KEDP evidence exists in a rat benign-prostatic-hyperplasia model. These are preclinical findings from lower-tier, non-independently-replicated sources.
Sources: Experimental studying of the drug efficiency Prostamax in the therapy of chronic aseptic prostatitis and its complications; Experimental Study of Efficiency of Tetrapeptide Lysyl-Glutamyl-Aspartyl-Proline Using the Model of Benign Prostatic Hyperplasia
Supported
Clinical evidence for animal-derived prostate polypeptide products (Prostatilen, Vitaprost) cannot be attributed to synthetic KEDP without an exact-compound study.
Supported
No adequate replicated modern clinical evidence was identified demonstrating that synthetic KEDP treats BPH, prostatitis, infertility, or prostate cancer.
Sources: MitoCore Batch 9 human-clinical-evidence literature search audit
Supported
Prostamax is not to be represented as an approved prostate therapy.
Sources: MitoCore Batch 9 regulatory search: FDA approval status and ClinicalTrials.gov registration check
Safety & Evidence Limitations
Considerations reported in the sources cited on this page — not a complete list of every possible risk, and not medical advice.
Safety Consideration
Clinical evidence for animal-derived prostate polypeptide products cannot be attributed to synthetic KEDP without an exact-compound study.Safety Consideration
The chronic aseptic prostatitis and BPH animal studies come from lower-tier journals and have not been independently replicated.Safety Consideration
No adequate replicated modern clinical evidence was identified demonstrating that synthetic KEDP treats BPH, prostatitis, infertility, or prostate cancer.
Research Areas Being Studied
Research areas discussed on this page reflect the Experimental / Early Research category and the sources cited below.
Findings Reported in Studies
Educational summary only — reported in cited studies, not a claim of proven benefit.
No Human Study Findings Listed Yet
See preclinical, regulatory, and review sources below.
Study Tables by Evidence Type
Human Studies & Clinical Data
No Human Studies & Clinical Data Listed Yet
This section will be updated as sources are added.
Animal / Cell / Preclinical Data
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| Experimental Study of Efficiency of Tetrapeptide Lysyl-Glutamyl-Aspartyl-Proline Using the Model of Benign Prostatic Hyperplasia | 2014 | Additional exact-sequence KEDP preclinical evidence in a rat benign-prostatic-hyperplasia model. | |||
| Experimental studying of the drug efficiency Prostamax in the therapy of chronic aseptic prostatitis and its complications | 2013 | Experimental chronic aseptic prostatitis animal model reporting reduced inflammation signs and prevention of sclerotic/atrophic changes with Prostamax; preclinical, not a human controlled trial. Lower-tier journal; not independently replicated. | |||
| Chromatin changes in old age involving Prostamax (Lys-Glu-Asp-Pro) | 2012 | Explicitly identifies the studied oligopeptide as Lys-Glu-Asp-Pro (KEDP) and reports chromatin-organization effects in an aging model. Direct exact-sequence KEDP evidence, compatible with the Prostamax identity established by patent RU2177802C1. | |||
| Prostamax effects on heterochromatin / human lymphocytes | 2004 | Direct indexed work reports effects of Prostamax on chromatin organization in human lymphocyte preparations. |
Regulatory Documents & Official Trial Registries
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| MitoCore Batch 9 regulatory search: FDA approval status and ClinicalTrials.gov registration check | 2026 | Direct search performed 2026-08-17 for FDA drug-approval status and ClinicalTrials.gov interventional-trial registration for PNC-27, Pancragen, Bronchogen, Testagen, Chonluten, Prostamax, Ovagen, and N-Acetyl Epitalon Amidate (Ac-AEDG-NH2), including known aliases and sequence names. No FDA-approved drug product was identified for any of the eight compounds. No registered ClinicalTrials.gov interventional trial was identified for any of the eight compounds. All eight are marketed exclusively through peptide/research-chemical vendors as research-use-only products, not as approved medicines. Absence from these searches is not itself a formal FDA determination and does not establish safety or ineffectiveness -- it establishes only that no approval or registered trial was located in this search pass. | |||
| RU2177802C1 -- Tetrapeptide regulating prostate function, pharmacological agent based on thereof and method of its using | Patent explicitly claims the tetrapeptide Lys-Glu-Asp-Pro ("lysyl-glutamyl-aspartyl-proline"), lists Prostamax as the associated trade name, states it is prepared by classical peptide synthesis in solution, and explicitly distinguishes it from Prostatilen (a prostate-tissue-derived polypeptide preparation). Confirms Prostamax = synthetic KEDP, separate from tissue extracts. |
Review Articles / Secondary Sources
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| Peptide epigenetic motif review including Prostamax | Broader paper on epigenetic-regulator peptides in rodents with long and short lifespans; NOT an exact Prostamax/KEDP identity paper. Should not be used as a core exact-identity citation -- RU2177802C1 and PMID 23221144 are materially stronger for identity. |
Anecdotal Reported Patterns — Not Medical Advice
Anecdotal Reported Patterns — Not Medical Advice
Reported dosing patterns are included for educational context only. They are self-reported, unverified, not medical advice, and not instructions for human use. Community-submitted patterns are not yet available in this Phase 1 prototype; this section is a placeholder reserved for moderated, aggregated community data.
Lab Markers to Discuss With a Clinician
Educational topics only — not self-monitoring instructions.
FAQ
Disclaimer
Educational information only. This page summarizes published research and does not provide medical advice, a recommendation, or instructions for human use.
Educational use only. This content is provided for informational and research-summary purposes only. It is not medical advice, not a treatment recommendation, not a dosing guide, and not a substitute for care from a licensed medical professional. Nothing here is intended to diagnose, treat, cure, prevent, or mitigate disease. Reported dosing patterns, when shown elsewhere on the site, must be labeled either as Study / Trial Dosing or Anecdotal Reported Patterns — Not Medical Advice. Community reports are self-reported, unverified, and not scientific proof.
Community-reported experiences, once enabled, must be displayed only as moderated, anonymized, or aggregated data. They are anecdotal, self-reported, unverified, and should never be presented as proof of safety, efficacy, or expected results.
Content status: Content pending review. Last updated 2026-08-17.
Follow research updates for Prostamax
Get notified in your MitoCore account when this profile is updated, a new study is added, or its evidence grade changes.
Get updates when new studies or safety notes are added for this peptide.
Get educational updates on new studies, evidence-grade changes, and safety notes. Educational content only — not medical advice.